This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Taurolidine is an antimicrobial derivative of taurine used for prophylaxis of catheter-related infections.
- Generic Name
- Taurolidine
- DrugBank Accession Number
- DB12473
- Background
Taurolidine has been investigated for the prevention of Central Venous Catheter, Home Parenteral Nutrition, and Catheter-Related Infections.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Taurolidine (DB12473)
- Weight
- Average: 284.35
Monoisotopic: 284.061297359 - Chemical Formula
- C7H16N4O4S2
- Synonyms
- Taurolidine
- External IDs
- W-3100M
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Associated Therapies
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAmbroxol The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Articaine. Benzocaine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Benzyl alcohol. Bupivacaine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Bupivacaine. Butacaine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Butamben. Capsaicin The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Capsaicin. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Chloroprocaine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Taurolidine is combined with Cinchocaine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- ATC Codes
- B05CA05 — Taurolidine
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as thiadiazinanes. These are organic heterocyclic compounds containing a six-membered saturated heterocycle with two nitrogen, one sulfur, and three carbon atoms.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Thiadiazinanes
- Sub Class
- Not Available
- Direct Parent
- Thiadiazinanes
- Alternative Parents
- Organosulfonamides / Organic sulfonamides / Azacyclic compounds / Aminals / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
- Substituents
- Aliphatic heteromonocyclic compound / Aminal / Azacycle / Hydrocarbon derivative / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organic sulfonic acid amide / Organic sulfonic acid or derivatives / Organonitrogen compound
- Molecular Framework
- Aliphatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 8OBZ1M4V3V
- CAS number
- 19388-87-5
- InChI Key
- AJKIRUJIDFJUKJ-UHFFFAOYSA-N
- InChI
- InChI=1S/C7H16N4O4S2/c12-16(13)3-1-10(5-8-16)7-11-2-4-17(14,15)9-6-11/h8-9H,1-7H2
- IUPAC Name
- 4-[(1,1-dioxo-1lambda6,2,4-thiadiazinan-4-yl)methyl]-1lambda6,2,4-thiadiazinane-1,1-dione
- SMILES
- O=S1(=O)CCN(CN2CCS(=O)(=O)NC2)CN1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 29566
- PubChem Substance
- 347828711
- ChemSpider
- 27486
- ChEBI
- 135173
- ChEMBL
- CHEMBL2105420
- ZINC
- ZINC000019322537
- Wikipedia
- Taurolidine
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Prevention Central Venous Catheterization / Parenteral Nutrition, Home 1 4 Unknown Status Prevention Catheter Related Infections 1 4 Unknown Status Prevention Hemodialysis Catheter Infection / Thrombosis; Dialysis Catheter 1 3 Completed Prevention Catheter Related Infections / Renal Failure, Chronic Renal Failure 1 3 Completed Prevention Infection / Parenteral Nutrition / Sepsis 1 3 Completed Treatment Infection / Patency 1 2 Completed Treatment Periodontitis 1 1 Completed Treatment Brain and Central Nervous System Tumors 1 1 Completed Treatment Fallopian Tube Cancer / Ovarian Cancer / Primary Peritoneal Cancer 1 1, 2 Completed Treatment Periodontitis 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Intraperitoneal 0.5 % Solution Intraperitoneal 2 % - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 16.2 mg/mL ALOGPS logP -2.1 ALOGPS logP -2.5 Chemaxon logS -1.2 ALOGPS pKa (Strongest Acidic) 10.53 Chemaxon pKa (Strongest Basic) 1.97 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 98.82 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 60.73 m3·mol-1 Chemaxon Polarizability 26.08 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at October 20, 2016 22:31 / Updated at May 27, 2021 02:58